The human breast cancer cell line UACC812, originally purchased from the American Type Culture Collection (Manassas, VA, USA), was cultured as previously reported (6 (link)). UACC812 cells resistant to lapatinib (LR) were derived from parental cells in vitro and maintained as previously described (6 (link)). Both parental and LR cell lines were authenticated by DNA sequencing and immediately frozen in our laboratory. Upon thawing, cell morphology, signaling, and sensitivity/resistance to L were maintained. L LC Laboratories, (Woburn, MA, USA) and ABT-737 (Selleckchem, Houston, Tx, USA) were dissolved in dimethyl sulfoxide (DMSO). Fulvestrant (Ful), AstraZeneca (London, UK), was prepared with ethanol.